Correction: Interleukin-6: a new therapeutic target
نویسندگان
چکیده
JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for coadministration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai.
منابع مشابه
The Role of Interleukin (IL-22) in immune response to human diseases
Background and aims: IL-22 is an alpha- helical cytokine. IL-22 binds to a heterodimeric cell surface receptor composed of IL-10R2 and IL-22R1subunits. IL-22R is expressed on tissue cells, and it is absent on immune cells. L-22 and IL-10 receptor chains play a role in cellular targeting and signal transduction to selectively initiate and regulate immune responses. The aim of this study was to i...
متن کاملThe Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis
Interleukin-6 is currently attracting significant interest as a potential therapeutic target in systemic sclerosis (SSc). In this paper, the biology of interleukin-6 is reviewed, and the evidence for interleukin-6 dysregulation in SSc is explored. The role of inteleukin-6 classical and trans signalling pathways in SSc relevant phenomena such as chronic inflammation, autoimmunity, endothelial ce...
متن کاملTherapeutic potential of Paclitaxel against COVID-19
The coronavirus disease-2019(COVID-19) was reported in Wuhan, China, in late December 2019 and soon became the most serious global health challenge due to high rate of human-to-human transmission. The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), is a single-stranded RNA virus and belongs to the large Coronaviridae family. Paclitaxel, an antineoplastic drug extracted from the Tax...
متن کاملInterleukin-6: a new therapeutic target in systemic sclerosis?
Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells, except lymphocytes and hepatocytes, express the functional membrane IL-6 receptor thus reducing the number of IL-6-responsive cells. Trans-signalling, t...
متن کاملInterleukin-6 Receptor: A Novel Therapeutic Target for Neuromyelitis Optica
Neuromyelitis optica (NMO) is an inflammatory disorder of the central nervous system causing optic neuritis and transverse myelitis. NMO typically has a worse prognosis than multiple sclerosis due the severity of the acute relapses which lead significant visual and motor impairment. Although the discovery of an NMO-IgG or aquaporin-4 antibody has led to greater understanding about the pathophys...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Arthritis Research & Therapy
دوره 8 شماره
صفحات -
تاریخ انتشار 2006